Pharmaceutical stocks erupt en masse! Subdivisions such as traditional Chinese medicine and medical devices have strengthened

【Pharmaceutical Network Pharmaceutical Stock Market】On September 29, the pharmaceutical stocks broke out collectively, and from the perspective of individual stocks, Dabo Medical, Baihua Pharmaceutical and other intraday rises and stops, Hengrui Pharmaceutical, Aohua Endoscopy, Adopt Shares, Xiangsheng Medical, Nanwei Medicine, Ruiang Gene, Zhifei Biological, Dongcheng Pharmaceutical, Zhongsheng Pharmaceutical, Xianju Pharmaceutical, Jiuzhou Pharmaceutical and other shares rose by more than 5%, in addition, WuXi AppTec, Foci Pharmaceutical, Tablet Zai Zhen, Tongrentang, Yiling Pharmaceutical, Mindray Medical, Tongce Medical, etc
.
followed suit.
From the perspective of its subdivision track, the eye-catching individual stocks are mainly concentrated in subdivisions such as traditional Chinese medicine, medical equipment, medical services, CRO, vaccines, and innovative drugs
.
Ping An Securities recently said that as of September 23, 2022, the valuation of the pharmaceutical sector was 21.
63 times (TTM, the overall method excluding negative values), and the valuation premium rate for all A-shares (excluding finance) was 19.
15%, lower than the historical average of 55.
62%, which is already at a low level, and the allocation of the pharmaceutical sector is cost-effective
.
Recently, the policy risks of the pharmaceutical sector have been released in a concentrated manner, and the national epidemic situation has also been well controlled, and at this time, we should pay attention to the marginal improvement of the upward trend
.
The bank believes that with the control of the epidemic, the performance of the pharmaceutical industry in the third quarter is expected to achieve accelerated growth, and in the medium and long term, pay attention to the basic aspects of the post-epidemic period
.
Up to now, a number of pharmaceutical companies have disclosed pre-increase announcements for third-quarter performance, for example, Kelun Pharmaceutical expects to achieve a net profit attributable to the mother in the third quarter of 447 million yuan to 574 million yuan, up 26% to 61% year-on-year; It is expected to achieve net profit attributable to the mother in the first three quarters of 1.
315 billion yuan to 1.
442 billion yuan, up 55% to 70%
year-on-year.
For the reasons for the pre-increase in performance, Kelun Pharmaceutical said that during the reporting period, the company made every effort to expand the market for infusion and non-infusion products, continued to optimize the product structure, increased the sales of newly approved products, and increased profits year-on-year; The market price of the main products of Yili Chuanning Biotechnology Co.
, Ltd.
, a holding subsidiary of the company, increased, and the profit increased year-on-year; The company's innovative R&D project A and a clinical early-stage biological macromolecule tumor project B are paid exclusive licenses to MSD to increase revenue and profits
.
For another example, BGI Intelligent Manufacturing, which landed on the A-share capital market on September 9, is expected to achieve operating income of about 3.
281 billion to 3.
441 billion yuan in the first three quarters of this year, an increase of 15.
26%-20.
88% year-on-year; It is expected to achieve attributable net profit of approximately 1.
893 billion to 2.
023 billion yuan, an increase of 311.
8% to 340.
08%
year-on-year.
It is reported that the company mainly focuses on the field of life science and biotechnology, with the research and development, production and sales of related products such as instruments and equipment, reagents and consumables as the main business, and the main products and services cover the gene sequencer business, laboratory automation business, and new business
.
Industrial Securities recently said that the preliminary analysis of the third quarter performance of the pharmaceutical sector still continued to grow relatively stable and fast, some segments due to the impact of the epidemic in Q2, and Q3 showed a state of
improvement from the previous quarter.
Considering that the previous plate adjustment led to the current low valuation, and the subsequent valuation switch will be gradually carried out, the cost performance of the pharmaceutical sector will be further highlighted
.
In terms of segmentation, it is expected that the Q3 of life science upstream, ophthalmic optometry, some domestic alternative medical devices, CXO, some vaccines, pharmacies and other sectors is expected to achieve better performance growth
.
Debon Securities believes that in the current environment, medicine is already in a state of low valuation and low allocation, and is expected to usher in a new round of strong period
.
Guojin Securities suggested that the follow-up focus should be on growth hormone, medical services, medical beauty, medical equipment, traditional Chinese medicine and other subdivision tracks, and the first stock repair opportunities
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.